A Major Breakthrough in CANCER!

For the first time in history, a team of scientists from the Memorial Sloan Kettering (MSK) Cancer Center in New York conducted an experimental immunotherapy trial. Shockingly, the trial resulted in 100% success rate. This research has taken the world by storm. The surprising positive results of this trial have given a ray of hope to cancer patients all over the world.

The Conduction of Experiment:

A total of 12 patients were taken under consideration for study. The patients involved were diagnosed with colorectal cancer, and were given provided with the same conditions and treatments. All the patients showed the same results of the experiment. A calculated dosage of the trial medicine, dostarlimab, was given to the patients at specific times. After six months, this drug yielded a major success rate in killing tutors completely. Along with the drug therapy, the common treatment of cancer (chemo-therapy, ration-therapy etc) was to be continued.

After six months, the experiment reached its completion, with the good news of elimination of all the cancer traces from the body. This treatment even removed the need of any radiation therapy or chemotherapy as a followup treatment. The most surprising part is that the disease has not reappeared in any of the patients, who have been cancer-free for up to two years.

It is also to be mentioned that the patients had no severe side effects during the therapy treatment. However, not many people participated in the experiment, as the results of medicine were not guaranteed, and could have had negative effects.

The Miracle Medicine:

This study took its inspiration from a former experiment, which involved the medication with the drug pembrolizumab; a humanized antibody used in cancer immunotherapy. It is slowly introduced that intravenous infusion. Patients involved in that study experienced their tumors stabilize, shrink, and in some cases, even complete elimination of cancer traces. Following the pattern of that study, this recent experiment was run with the drug dostarlimab; a monoclonal antibody. This medication was tried on patients whose cancer was not mutated throughout the body. Dostarlimab strengthens the immune system and urges the immunity to locate and attack cancer cells.

According to the researchers, this immunotherapy shrank the tumors at a faster rate than was expected. Even after only one treatment, the patients felt a great relief in their pain intensity and their bleeding was also controlled.

The Future:

It is not yet known if the results of this experiment would be able to capture the broader spectrum or not, but the results have surely risen hope among the suffering patients, and a major advancement in field of health and medical science. This advancement is a tip of the iceberg. The doctors are now more determined to devise methods of treating various kinds of cancers. Currently the patients with gastric, prostrate and pancreatic cancer have been enrolled for experiment. 

This research has been presented at the largest clinical oncology conference in June 2022.